1. Senkyunolide I may be an active component of L. chuanxiong, traditionally used to treat migraine, the mechanism of pain relief in migraine model rats may be through adjusting the levels of monoamine neurotransmitters and their turnover rates, as well as decreasing nitric oxide levels in the blood and brain; therefore, senkyunolide I may be developed as a potential treatment for migraine pain.
2. Senkyunolide I can reduce the metamorphose damage of the RBC caused by ConA, the aggregation of the RBC can be alleviated by it.
3. Senkyunolide I can protect rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3, the neuroprotective mechanisms of itI are associated with its anti-oxidation and anti-apoptosis properties.
Parthenolide exhibits anti-cancer, anti-inflammatory, immunomodulatory, anti-Leishmania, and antimigraine effects, it inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel.Parthenolide is also an inhibitor of the nuclear factor-kappaB pathway, can ameliorate cardiovascular derangement and outcome in endotoxic shock in rodents.